Month: August 2026

IVF Attrition Explained: Where Eggs and Embryos Are Lost During Treatment

Twelve eggs are retrieved during IVF. Nine are mature. Six fertilise. Three reach the blastocyst stage.

Watching those numbers fall can be one of the most confronting parts of fertility treatment, particularly when the initial egg retrieval created expectations of having many embryos available.

But this progressive reduction—often called IVF attrition—does not automatically mean something has gone wrong. It reflects the multiple biological stages an egg must successfully pass through before becoming an embryo potentially suitable for transfer.

IVF attrition is the reduction in numbers between egg retrieval, egg maturity, fertilisation and embryo development. Not every follicle produces an egg, every retrieved egg is not necessarily mature, every mature egg will not fertilise, and every fertilised egg will not reach the blastocyst stage. The amount of attrition varies considerably between patients and cycles.

Why Do IVF Numbers Drop So Quickly?

IVF makes reproductive biology visible.

During unassisted conception, eggs may not fertilise and fertilised eggs may stop developing without anyone knowing it happened. IVF moves several of these stages into the laboratory, where each can be observed and counted.

The American Society for Reproductive Medicine (ASRM) notes that approximately 70% of mature eggs typically fertilise during IVF and around half of fertilised eggs subsequently develop to the blastocyst stage. These are broad population estimates, not predictions for an individual treatment cycle.

This means the number of eggs retrieved should never be interpreted as the number of embryos a patient will ultimately have.

Each stage has a different biological requirement.

Stage 1: Follicles Do Not Always Equal Eggs

During ovarian stimulation, ultrasound is used to monitor follicles developing within the ovaries.

If 12 follicles are visible before retrieval, it is easy to mentally convert that into 12 eggs.

The numbers are not necessarily identical.

A follicle is the fluid-filled ovarian structure in which an oocyte—an egg cell—develops. Follicles can differ in size and developmental stage, and not every follicle necessarily yields an egg during retrieval.

The number of eggs collected can therefore be lower than the follicle count seen on ultrasound.

This is the first potential point of attrition.

Stage 2: Not Every Retrieved Egg Is Mature

An egg also needs to reach the appropriate developmental stage before it can normally fertilise.

For IVF and intracytoplasmic sperm injection (ICSI), the laboratory assesses egg maturity. A mature egg has generally reached metaphase II (MII).

Some retrieved eggs may still be immature.

This creates an important distinction between eggs retrieved and mature eggs available for fertilisation.

For example, retrieving ten eggs does not necessarily mean ten eggs can undergo ICSI.

Egg maturity can be influenced by follicular development, ovarian stimulation, timing of the trigger medication and individual biological variation.

Stage 3: Not Every Mature Egg Fertilises

Fertilisation creates another major reduction.

In conventional IVF, sperm and eggs are placed together in the laboratory. With ICSI, an embryologist injects a single sperm into a mature egg.

Neither technique guarantees fertilisation.

Normal fertilisation is generally identified by the appearance of two pronuclei containing maternal and paternal genetic material.

ASRM estimates that approximately 70% of mature eggs fertilise during IVF.

Individual results can be considerably higher or lower.

Egg factors, sperm factors and other biological variables can influence this stage.

This is also why unexpectedly low fertilisation should be considered separately from overall IVF attrition. If very few—or none—of the mature eggs fertilise, the fertility team may investigate that particular stage rather than describing the entire cycle simply as unsuccessful.

Going through IVF can generate an overwhelming amount of information. Create your free Sistapedia® profile to explore trusted fertility information and discover verified reproductive-health professionals.

Stage 4: Fertilised Eggs Can Stop Developing

Successful fertilisation does not guarantee continued embryo development.

After fertilisation, an embryo begins dividing. By approximately day three it is generally described as a cleavage-stage embryo.

Some embryos continue developing normally.

Others stop.

This is known as embryonic arrest.

Embryo development requires a highly coordinated sequence of cellular and genetic processes. An embryo can therefore fertilise normally but fail to continue developing.

This explains why a promising fertilisation report can be followed several days later by a much smaller number of developing embryos.

Stage 5: Not Every Embryo Reaches Blastocyst

A blastocyst is an embryo that has usually developed for approximately five or six days after fertilisation and reached a more advanced cellular structure.

ASRM estimates that approximately half of fertilised eggs typically continue to blastocyst.

Again, this is an average rather than an individual target.

Some patients may have a high blastocyst conversion rate. Others may have substantially fewer embryos reach this stage.

Clinicians also cannot predict with certainty which early embryos will ultimately develop into viable blastocysts.

That uncertainty is part of IVF biology.

Why Does Age Matter?

Age can affect the IVF funnel because egg number and chromosomal competence are different issues.

As maternal age increases, the probability of chromosomal abnormalities in embryos generally increases.

An embryo with an abnormal chromosome number is described as aneuploid. An embryo with the expected chromosome complement is described as euploid.

Age-related aneuploidy is an important contributor to implantation failure and miscarriage.

This means two women who retrieve the same number of eggs can ultimately have very different embryo outcomes.

Egg quantity is therefore only one part of IVF prognosis.

Does PGT-A Cause Another Drop in Embryo Numbers?

For patients using preimplantation genetic testing for aneuploidy (PGT-A), another selection stage may occur after blastocyst development.

Appropriate blastocysts can be biopsied and assessed for chromosome copy-number abnormalities. Results may include euploid, aneuploid or more complex findings such as mosaic results.

However, PGT-A is not a universal requirement in IVF.

ASRM states that the value of PGT-A as routine screening for every IVF patient has not been established. Whether it is appropriate depends on individual circumstances and should be discussed separately with the fertility team.

Does High IVF Attrition Mean Something Went Wrong?

Not necessarily.

The most important question is where the attrition occurred.

Few mature eggs raise different questions from poor fertilisation.

Poor fertilisation is different from repeated embryo arrest.

And producing blastocysts that subsequently fail to implant represents another clinical issue again.

Rather than focusing only on the first and final numbers, ask for the results at each transition:

retrieved eggs → mature eggs → normally fertilised eggs → developing embryos → blastocysts

This makes it easier to identify whether the cycle followed a broadly expected pattern or whether one particular stage produced an unexpected result.

Can the Next IVF Cycle Be Different?

Yes.

A previous cycle provides useful information about ovarian response, egg maturity, fertilisation and embryo development, but it does not guarantee identical results in another cycle.

Egg yield can change. Maturity can change. Fertilisation can change. Embryo development can change.

Clinicians may also adjust treatment based on information learned during an earlier cycle.

This variability is one reason comparing your IVF numbers with another patient’s results can be misleading.

Age, diagnosis, ovarian reserve, sperm factors, treatment protocols and other circumstances may differ considerably.

When to Discuss IVF Attrition With Your Fertility Specialist

Some attrition is expected.

A more detailed review may be particularly useful when no mature eggs are obtained, fertilisation is substantially lower than expected, fertilisation fails completely, no embryos reach blastocyst or a similar pattern occurs repeatedly across treatment cycles.

Ask your fertility specialist which stage produced the unexpected result and whether it represents normal biological variation or something requiring further investigation.

A more useful question than “Why did we lose so many embryos?” is:

“At which stage did our results differ from what you expected for my circumstances?”

That focuses the discussion on information that may actually influence future treatment.

IVF Attrition Is a Funnel, Not a Straight Line

The emotional difficulty of attrition often comes from mentally carrying the first number through to the end.

Twelve eggs can feel like 12 potential embryos.

Biologically, that is not what the number represents.

Retrieval creates a starting population. The eggs must then pass through maturity, fertilisation and continued embryo development before reaching blastocyst.

The numbers narrow because human reproduction itself involves substantial biological selection.

Understanding this does not make seeing embryo numbers fall easy.

But it does change what those numbers mean.

IVF attrition is not automatically evidence that your body failed or that treatment failed. What matters clinically is where attrition occurred, whether it was unexpected for your circumstances and what that information may reveal about the treatment cycle.

FAQs

How many retrieved eggs usually fertilise during IVF?

ASRM estimates that approximately 70% of mature eggs typically fertilise. This is a broad population estimate and individual results vary.

How many fertilised eggs usually reach blastocyst?

Approximately half of fertilised eggs may reach the blastocyst stage according to ASRM estimates, but outcomes vary considerably between patients and cycles.

Is it normal for embryos to stop developing before day 5?

Yes. Some embryos stop developing before reaching blastocyst. The clinical significance depends on the individual cycle and whether an unexpected pattern occurs repeatedly.

Does getting lots of eggs mean I will get lots of embryos?

No. Retrieved eggs must also be mature, fertilise normally and continue developing. Egg retrieval numbers therefore cannot predict the final number of blastocysts on their own.

Does IVF attrition mean poor egg quality?

Not automatically. Attrition can occur at several stages and may involve multiple biological factors. Identifying the specific stage where unexpected attrition occurred is more informative than the overall reduction.

Continue on Sistapedia®

For Sistas: Create your free Sistapedia® profile to explore trusted reproductive-health information and discover verified fertility professionals.

Your IVF experience could help another woman understand her own treatment. Share your story on Sistapedia® and apply for your free Pink Tick verification.

For fertility professionals and Experts: Establish your verified professional presence, publish educational content and strengthen discovery across Sistapedia®. Apply for Crown Verification through the Verification tab in your profile.

Sources

• American Society for Reproductive Medicine — It Takes More Than One: Why IVF Patients Often Need Multiple Embryos to Have a Baby.
• American Society for Reproductive Medicine — Blastocyst Culture and Transfer in Clinically Assisted Reproduction.
• American Society for Reproductive Medicine — guidance on preimplantation genetic testing for aneuploidy.

What Your Period Can Reveal About Your Overall Health

Your period is not simply a monthly reproductive event. Changes in its timing, frequency, duration and flow can sometimes provide useful information about what is happening elsewhere in your body.

That does not mean every unusual period signals disease. Menstrual cycles naturally change with age, contraception, pregnancy, breastfeeding and the transition to menopause. But when your established pattern changes significantly—or periods repeatedly interfere with everyday life—the change deserves attention.

Menstrual patterns can reflect reproductive and overall health because menstruation depends on coordinated signalling between the brain, ovaries and uterus. Irregular, absent, unusually frequent or very heavy periods can sometimes occur with conditions including PCOS, thyroid disorders, pregnancy, primary ovarian insufficiency, bleeding disorders and inadequate energy intake. A period cannot diagnose these conditions, but changes can provide an important reason for further assessment. (ACOG⁠)

Why Is the Menstrual Cycle Sometimes Called a Vital Sign?

The idea has a clinical basis.

The American College of Obstetricians and Gynecologists (ACOG) describes menstrual patterns as an additional vital sign in adolescents because recognising abnormal patterns can help identify underlying health concerns. Its guidance was reaffirmed in 2025. (ACOG⁠)

The principle extends beyond adolescence: menstruation is the visible endpoint of a complex hormonal process.

The hypothalamus and pituitary gland in the brain communicate with the ovaries through the hypothalamic-pituitary-ovarian (HPO) axis. The ovaries produce hormones including estrogen and progesterone. Those hormonal changes influence ovulation and the endometrium—the lining of the uterus that is shed during menstruation when pregnancy has not occurred.

Disruption at different points in this system can alter the cycle.

That is why a menstrual history can contain useful clinical information.

What Is Considered a Regular Period?

There is no single menstrual pattern that every woman should have.

For adults in their 20s and 30s, the U.S. Office on Women’s Health describes cycles of approximately 24 to 38 days as typical. Cycles can be less predictable during the first years after menstruation begins and again during perimenopause. (Office on Women’s Health⁠)

What matters is not only whether your cycle fits a population average, but whether there has been a meaningful change from your usual pattern.

Tracking the first day of each period, how long bleeding lasts, changes in flow and significant symptoms can make those changes easier to identify.

What Can Irregular Periods Mean?

An irregular period is a symptom, not a diagnosis.

The Office on Women’s Health defines adult cycles as irregular when they occur less than 24 or more than 38 days apart, or when cycle length varies by more than 20 days from month to month. (Office on Women’s Health⁠)

There are many possible explanations.

Pregnancy is an obvious reason for a missed period in someone who could be pregnant. Hormonal contraception can intentionally change bleeding patterns. Breastfeeding can delay the return of regular ovulation and menstruation after birth.

Other causes require more investigation.

Thyroid disorders can alter menstrual frequency and flow because thyroid hormones interact with reproductive function. Elevated prolactin—hyperprolactinemia—can also disrupt menstruation.

Major changes in nutrition, exercise or energy availability can interfere with hypothalamic signalling and suppress ovulation. This can produce amenorrhea, meaning absent menstruation, or oligomenorrhea, meaning infrequent periods.

The important question is therefore not simply,

“Are my periods irregular?”

It is: Why has my menstrual pattern changed?

Could Irregular Periods Be a Sign of PCOS?

Yes, but irregular periods alone do not establish polycystic ovary syndrome (PCOS).

PCOS can interfere with normal follicle development and ovulation, resulting in missed, infrequent or irregular periods. The Office on Women’s Health estimates PCOS affects approximately one in ten women of childbearing age. (Office on Women’s Health⁠)

Other signs can include increased facial or body hair, acne and scalp hair thinning associated with androgen excess.

Because other conditions can produce similar symptoms, PCOS assessment involves more than recognising an irregular cycle. Clinicians may consider menstrual history, signs or laboratory evidence of elevated androgens, other hormone testing and, where appropriate, ultrasound findings.

Your cycle may therefore provide a clue. It does not provide the diagnosis.

What Can Heavy Periods Tell You?

Heavy menstrual bleeding deserves particular attention because it can be both a symptom and a cause of another health problem.

The CDC describes signs of heavy menstrual bleeding as including bleeding lasting more than seven days, needing to change a pad or tampon in less than two hours, soaking through menstrual products hourly for several hours, passing large clots or having bleeding substantial enough to restrict normal activities. (CDC⁠)

Heavy bleeding can contribute to iron-deficiency anaemia through repeated blood loss.

Symptoms of anaemia can include fatigue, weakness and shortness of breath.

But heavy bleeding can also occasionally indicate an underlying bleeding disorder. The CDC notes that heavy menstrual bleeding, anaemia and other patterns of easy or frequent bleeding can be signs of a bleeding disorder. (CDC⁠)

Fibroids, ovulatory dysfunction and other gynaecological conditions can also alter bleeding.

The key point is simple: consistently heavy periods should not automatically be accepted as “just how my body works.”

If your menstrual pattern has changed, create your free Sistapedia® profile to explore trusted reproductive-health information and discover verified professionals relevant to your health journey.

What If Your Period Suddenly Stops?

The medical term for absence of menstruation is amenorrhea.

Pregnancy should usually be considered first when biologically possible, but it is far from the only explanation.

Periods can stop when the reproductive system receives signals that conditions are not suitable for normal ovulation.

Substantial weight loss, inadequate energy intake, intensive exercise and eating disorders can affect the HPO axis. ACOG notes that delayed or absent menstruation may sometimes be a presenting symptom in adolescents and young women with an undiagnosed eating disorder. (ACOG⁠)

Other possibilities include PCOS, thyroid disorders, elevated prolactin, some medications and primary ovarian insufficiency.

Primary ovarian insufficiency (POI) occurs when ovarian function becomes impaired before age 40. It is not simply another term for menopause, and absent or increasingly irregular periods in a younger woman require appropriate assessment rather than assumptions about the cause. (Office on Women’s Health⁠)

Can Your Period Reflect Stress?

Stress can influence menstrual function, but it is important not to use “stress” as an automatic explanation for every cycle change.

The brain is directly involved in reproductive hormone signalling. Significant physical or psychological stress can affect hypothalamic function and consequently ovulation and menstruation.

Illness, undernutrition, major weight change and intensive physical training can also create physiological stress.

But persistent menstrual abnormalities still warrant investigation where appropriate.

A thyroid disorder, PCOS or another medical condition should not be overlooked because a woman happens to be experiencing a stressful period in her life.

What Does Period Pain Reveal?

Some discomfort during menstruation is common, but severe pain that repeatedly disrupts normal activities should not simply be normalised.

Painful menstruation is called dysmenorrhea.

Primary dysmenorrhea occurs without another pelvic disease and is associated with prostaglandins involved in uterine contractions.

Secondary dysmenorrhea occurs because of an underlying condition.

Endometriosis, adenomyosis and fibroids are among the conditions that can be associated with menstrual pain.

The intensity of pain alone cannot identify which condition, if any, is responsible. The pattern matters: when the pain began, whether it is worsening, whether it occurs outside menstruation and whether there are additional symptoms such as pain during sex, abnormal bleeding or bowel and bladder symptoms.

Your Period Changes Across Your Reproductive Life

A healthy menstrual pattern is not necessarily identical at 16, 26 and 46.

Cycles are commonly less predictable in the years immediately after menarche—the first menstrual period—as hormonal regulation matures.

Through much of adulthood, cycles often become more predictable.

During perimenopause, changing ovarian function can make periods shorter, longer, heavier, lighter or increasingly irregular. The Office on Women’s Health notes that women in their 40s may skip periods for one or several months before bleeding returns. (Office on Women’s Health⁠)

Context therefore matters.

A cycle pattern that can be expected during perimenopause could require a different interpretation in a 25-year-old.

Age does not, however, mean every bleeding change should automatically be attributed to menopause. New abnormal bleeding still requires assessment when clinically indicated.

Why Tracking Your Period Is Clinically Useful

Period tracking does not need to become an obsession with daily data.

A simple record can be useful.

Record when bleeding begins, approximately how long it lasts, whether flow is unusually heavy or light, significant pain, bleeding between periods and major changes in cycle length.

If symptoms develop, this provides something more useful than trying to reconstruct six months of cycles from memory during a medical appointment.

The purpose is not to make your own diagnosis.

It is to recognise your pattern—and notice when that pattern meaningfully changes.

When to Seek Medical Assessment

Speak with a healthcare professional if your periods suddenly become substantially different from your usual pattern, repeatedly occur outside the expected range for your life stage, disappear unexpectedly, become very painful or interfere with work, school or normal activities.

Heavy bleeding also warrants assessment. Seek medical advice if bleeding lasts longer than seven days, requires very frequent menstrual-product changes, involves repeated large clots or is associated with fatigue, weakness or shortness of breath. (CDC⁠)

Bleeding during pregnancy, after menopause or accompanied by severe pain, fainting or other acute symptoms requires appropriate medical assessment rather than routine cycle tracking.

Your Period Is Information, Not a Diagnosis

Menstruation provides a recurring window into a complex biological system.

Changes can sometimes reveal disturbances in ovulation, endocrine function, energy availability, blood loss or reproductive ageing. At other times, variation is completely consistent with the life stage you are in.

The value lies in recognising the difference.

Your period cannot tell you that you have PCOS, thyroid disease, endometriosis, anaemia or another condition.

But it can tell you that something has changed.

And sometimes that is the first information needed to investigate why.

FAQs

What does an irregular period say about your health?

Irregular periods can occur normally during adolescence and perimenopause, but they can also be associated with pregnancy, PCOS, thyroid disorders, elevated prolactin, changes in energy availability, some medications and other conditions.

Can your period show that you have a hormone imbalance?

Changes in menstruation can occur when hormonal signalling is disrupted, but a period cannot identify which hormone is responsible. Clinical history and appropriate testing are needed when an endocrine condition is suspected.

How do you know if your period is too heavy?

Signs include bleeding for more than seven days, needing to replace menstrual products in less than two hours, repeatedly soaking through products hourly, passing large clots or having bleeding that interferes with normal activities. (CDC⁠)

Can stress make you miss your period?

Significant physiological or psychological stress can disrupt the hormonal signalling involved in ovulation and menstruation. Persistent missed periods should still be assessed rather than automatically attributed to stress.

Should I track my menstrual cycle?

Tracking can help establish your normal pattern and provide useful information if bleeding, pain or cycle timing changes. It can also make discussions with a healthcare professional more specific. (Office on Women’s Health⁠)

Continue on Sistapedia®

For Sistas: Create your free Sistapedia® profile to access trusted reproductive-health information and discover verified participants across the reproductive-health ecosystem. A free Pink Tick signals that you have completed identity verification as a genuine human participant.

Share your experience: Your experience could help another woman recognise changes in her own reproductive health. Share your story and contribute to the Sistapedia® community.

For qualified professionals and commercial participants: Establish your verified presence and publish educational content across Sistapedia®. Eligible Medical Doctors, Doctors of Osteopathic Medicine, General Practitioners, Registered Nurses, Healthcare Practitioners, Experts, Products and Brands can apply through the Verification tab in their profile.

The Menopause Economy: Which Companies Are Competing for the Midlife Woman?

Menopause has become a serious commercial healthcare category spanning virtual clinics, pharmaceuticals, employer benefits and consumer health. Here is how the market is taking shape and where competition is intensifying.

For decades, menopause occupied an unusual commercial blind spot. Almost every woman who reaches midlife experiences the biological transition, yet healthcare provision, product development and investment remained fragmented.

That is changing. Menopause now attracts specialist virtual clinics, pharmaceutical manufacturers, employer-benefit platforms, established healthcare networks and consumer-health companies. The commercial contest is no longer simply about selling menopause products. Increasingly, it is about who earns and retains the relationship with women throughout midlife.

The menopause economy is developing into a multi-layered healthcare market spanning clinical care, prescription medicines, employer benefits, digital health and consumer products. Companies compete through very different business models, and the strongest commercial positions may ultimately belong to those controlling trusted access and distribution—not necessarily those offering the largest individual product range.

Why Menopause Became a Commercial Healthcare Category

The demographic opportunity is substantial.

Bayer estimates that approximately 1.2 billion women globally will be experiencing menopause by 2030, with around 47 million entering the transition each year. Vasomotor symptoms such as hot flashes affect up to 80% of women during the menopausal transition.

But population size alone does not create a market.

Several changes occurred simultaneously.

Women became more willing to discuss symptoms publicly. Telehealth reduced dependence on finding local menopause expertise. Employers began incorporating menopause into broader women’s-health benefits. Pharmaceutical development expanded beyond conventional hormone therapy. Investors increasingly recognised that midlife women represented a large population with significant unmet healthcare needs.

Menopause consequently shifted from an underdeveloped segment of women’s healthcare into a competitive commercial ecosystem.

Virtual Clinics Are Competing for the Care Relationship

One of the clearest changes has been the emergence of specialist virtual care.

Companies including Midi Health, Evernow and Gennev entered the market through digitally delivered clinical care rather than a single physical product.

That model has an important commercial advantage.

A woman might initially seek help for hot flashes but subsequently need support for sleep, vaginal symptoms, sexual health, bone health or other midlife concerns. The clinical relationship can therefore extend well beyond the original symptom.

Evernow has expanded its access model beyond membership care by introducing pay-per-visit consultations.

Gennev followed a different path. Unified Women’s Healthcare acquired the digital menopause platform in 2022, incorporating specialist menopause capability into a much larger women’s-health network.

The acquisition demonstrated that menopause expertise can create value not only as a standalone digital business but as specialist infrastructure within broader healthcare delivery.

Midi Health Signals the Scale Investors See in Midlife Care

Midi Health provides one of the strongest recent signals of investor interest in the category.

In 2026, reporting placed the company’s valuation at approximately $1 billion following a new funding round, with Midi reportedly providing virtual care to more than 20,000 women each week.

The significance extends beyond the valuation.

A billion-dollar valuation attached to a business that established its position through perimenopause and menopause care challenges the idea that midlife women’s health is a narrow commercial niche.

It also changes the competitive question.

The issue is increasingly not whether menopause can support substantial healthcare businesses, but which companies can capture and retain the relationship with women seeking care.

Employer Benefits Created Another Economic Customer

The woman receiving menopause care is not necessarily the only customer paying for access.

Employers increasingly purchase reproductive, family and women’s-health benefits for employees.

Maven Clinic illustrates this model. Its services extend beyond menopause, but menopause and midlife care now form part of its employer proposition.

Maven reported in 2026 that 47% of members experiencing severe menopause symptoms said access to Maven made them more likely to remain with their employer. The company has also reported improvements in symptom severity among members using its menopause services. These are company-reported outcomes rather than independent comparative clinical evidence, but they demonstrate the commercial case being presented to employers.

This creates a business-to-business-to-consumer model.

Instead of acquiring every woman individually, a healthcare platform can secure an employer relationship covering potentially thousands of eligible employees.

For menopause companies, competition therefore extends beyond patients to employers, insurers and benefits distribution.

For women’s-health companies, commercial visibility increasingly depends on more than having a strong product or service. Establish your verified commercial identity on Sistapedia® through the Verification tab in your profile.

Pharmaceutical Companies Are Competing With New Mechanisms

The pharmaceutical landscape is also changing.

Hormone therapy remains an important treatment for many appropriate women, but innovation has expanded into non-hormonal treatments.

Astellas introduced fezolinetant, a neurokinin 3 receptor antagonist, in the United States as Veozah in 2023.

Bayer subsequently introduced elinzanetant, marketed as Lynkuet, a dual neurokinin 1 and neurokinin 3 receptor antagonist for moderate to severe vasomotor symptoms. The FDA approved Lynkuet in October 2025.

Bayer’s 2026 investor materials described Lynkuet as having “blockbuster potential,” signalling expectations for substantial commercial demand.

This changes the composition of the menopause market.

Specialist clinics and consumer companies are no longer developing the category alone. Major pharmaceutical manufacturers are investing in patented therapies specifically targeting menopausal symptoms.

Their commercial model differs from virtual clinics. Pharmaceutical companies do not necessarily need to own the entire patient relationship. They can reach women through established prescribing and healthcare networks.

Consumer Companies Compete Symptom by Symptom

Outside prescription healthcare sits another large and fragmented market.

Women experiencing menopause may encounter supplements, lubricants, vaginal moisturisers, skin care, hair products, cooling products, sleep products and other consumer offerings marketed around midlife symptoms.

This creates numerous commercial entry points, but also considerable fragmentation.

One woman may obtain clinical care from one company, prescriptions from another, supplements from another and information elsewhere.

No single participant necessarily sees the complete journey.

That fragmentation creates opportunity for companies but makes navigation harder for consumers. Women must distinguish between evidence-based clinical treatment, regulated medicines, wellness products and marketing claims.

Winning an individual product transaction therefore does not necessarily mean winning the longer-term relationship.

Distribution May Matter More Than Product Volume

Product innovation receives attention, but distribution could determine many of the eventual winners.

Menopause companies can reach women through clinicians, health systems, insurers, employers, pharmacies, retailers, digital platforms and direct consumer acquisition.

Each route changes cost, scale and trust.

Gennev gained access to a larger women’s-health network through Unified. Maven reaches women through employers. Virtual clinics combine direct acquisition with insurance and healthcare relationships. Pharmaceutical companies use established prescribing channels while also investing in consumer awareness.

Different models therefore converge on the same commercial objective:

reach the appropriate woman when she decides to seek information, treatment or a product.

A company with a strong offering but expensive customer acquisition may struggle against a competitor already embedded within an employer, insurer, health system or trusted professional network.

Menopause Is Becoming an Entry Point Into Midlife Health

Menopause also overlaps with cardiovascular health, metabolism, sleep, bone health, sexual health, pelvic health and preventive medicine.

That makes the transition commercially important as an entry point rather than merely a temporary symptom category.

A company that establishes trust during perimenopause could potentially maintain that relationship long after a woman’s final menstrual period.

This may explain why some businesses are expanding beyond narrow menopause positioning towards broader midlife or women’s-health models.

The commercial distinction is substantial.

A menopause service competes for an episode of need.

A comprehensive midlife-health platform potentially competes for a relationship lasting decades.

What Could Determine the Winners?

There is no verified evidence establishing which company will ultimately dominate the menopause economy. Private-company financial data is also limited.

Several competitive factors are nevertheless visible.

Clinical credibility matters because healthcare scale cannot sustainably separate from evidence and patient safety.

Distribution matters because trusted access can lower the cost and difficulty of reaching women.

Reimbursement matters because consumer behaviour changes when care is covered by insurers or employers.

Regulation matters because prescription medicines, medical services, devices, supplements and consumer products operate under different rules.

Integration may matter most of all.

Women do not experience menopause as separate commercial categories. Symptoms, clinical treatment, products and services frequently intersect.

Companies capable of connecting those needs without making healthcare more complicated could hold an important structural advantage.

The Menopause Economy Remains Fragmented

Menopause has moved firmly into mainstream healthcare investment and commercial strategy, but the market has not consolidated around one dominant model.

Specialist clinics compete for clinical relationships. Employer platforms compete for workforce distribution. Pharmaceutical manufacturers compete through proprietary treatments. Healthcare networks acquire specialist capability. Consumer companies compete symptom by symptom.

The result is not one menopause market.

It is a collection of overlapping markets competing for the same woman at different moments in her midlife health journey.

That changes the commercial challenge.

Innovation alone is insufficient.

The defining question is increasingly:

How does the appropriate woman discover, trust and access a company when its product or service becomes relevant to her?

For the next phase of the menopause economy, the answer may determine which companies convert the enormous demographic opportunity into durable commercial leadership.

FAQs

Why are so many companies entering the menopause market?

Menopause combines a large global population, historically underserved healthcare demand, greater public awareness and expanding digital care, employer benefits and pharmaceutical treatment options.

Which companies are competing in menopause healthcare?

The market includes specialist platforms such as Midi Health and Evernow, Gennev within Unified Women’s Healthcare, broader women’s-health platforms such as Maven Clinic, pharmaceutical companies including Astellas and Bayer, and numerous consumer-health companies.

Why are employers paying for menopause care?

Employers increasingly consider menopause support within workforce health, retention and benefits strategies. This creates another distribution channel for menopause healthcare companies.

Is menopause mainly a telehealth market?

No. Telehealth is one model within a broader ecosystem including conventional healthcare, pharmaceuticals, employers, insurers, pharmacies and consumer products.

Will one company dominate menopause care?

There is currently insufficient verified evidence to support that conclusion. Different companies hold advantages in clinical care, pharmaceutical innovation, employer distribution and healthcare networks.

Participate in the Sistapedia® Ecosystem

Products & Brands and Service Providers: Establish your verified commercial identity through the Verification tab in your Sistapedia® profile. Publish relevant educational content and establish your presence across the reproductive-health ecosystem.

Eligible SistaShop™ participation follows applicable verification, eligibility, claims, jurisdiction and availability requirements.

Healthcare Professionals and Experts: Verify your credentials, establish your professional presence and publish educational content. Apply for Crown Verification through the Verification tab in your Sistapedia® profile.

Sistas: Participation is free. Your experience could help another woman understand her own. Share your story on Sistapedia® and apply for your free Pink Tick verification.

Secure your position early.

Smart Rings and Women’s Health: What Can Wearables Actually Detect?

A ring on your finger can now collect thousands of physiological measurements while you sleep. For women, that creates an appealing possibility: could a wearable detect ovulation, explain cycle changes, identify pregnancy, flag perimenopause or even warn that something is wrong before symptoms become obvious?

The answer is more nuanced than the marketing around wearable health technology sometimes suggests.

Smart rings can identify patterns in temperature, heart rate, heart-rate variability, sleep and other physiological signals that change across the menstrual cycle. Some technologies can estimate cycle phases and ovulation with useful accuracy. But most consumer wearables are not diagnostic devices, and a physiological pattern is not the same thing as a medical diagnosis.

Smart rings are increasingly capable of detecting physiological changes associated with menstrual cycles, ovulation, sleep, recovery and other aspects of women’s health. Their strongest value is longitudinal pattern recognition: comparing your body with its own baseline over time. They cannot independently diagnose PCOS, endometriosis, infertility, pregnancy complications or menopause.

Why a Smart Ring Can See More Than a Period-Tracking Calendar

Traditional period trackers depend heavily on information entered by the user: when bleeding started, how long it lasted and what symptoms occurred.

A wearable adds another layer—continuous physiological data.

Depending on the device, a smart ring may measure:

• skin temperature trends;
• resting heart rate;
• heart-rate variability (HRV);
• respiratory rate;
• sleep duration and stages;
• movement and activity;
• blood oxygen-related measurements.

That matters because reproductive hormones do not only affect the ovaries and uterus. Hormonal changes can influence body temperature, cardiovascular function, sleep and other systems.

Progesterone is one of the clearest examples.

After ovulation, progesterone rises during the luteal phase of the menstrual cycle and produces a small increase in body temperature. Oura notes that menstrual-cycle temperature shifts are generally around 0.3°C to 0.7°C. (Oura Ring⁠)

A ring worn consistently overnight can look for this pattern rather than relying entirely on an assumed 28-day cycle.

That distinction is important because human menstrual cycles are not clocks.

Can Smart Rings Detect Ovulation?

This is one of the most promising reproductive-health applications.

Ovulation itself cannot simply be “seen” by a consumer ring. Instead, algorithms analyse physiological changes that occur around it.

Research is increasingly supporting this approach. In data published by Oura for clinicians, its ring detected ovulation in 96.4% of evaluated cycles, with 87.9% of detections falling within two days of the ovulation date when positive luteinising hormone (LH) tests were used as the reference. The mean absolute error reported for the ring was 1.26 days, compared with 3.44 days using a calendar method. (Oura Ring⁠)

That does not mean a ring can predict the exact moment an egg is released.

There is also an important distinction between predicting ovulation and confirming that physiological changes consistent with ovulation have occurred.

Temperature generally rises after ovulation because progesterone has increased. This makes temperature particularly useful for recognising the transition into the luteal phase retrospectively.

Oura’s current Cycle Insights system, for example, states that several days of temperature data may be required before ovulation is confirmed. (Oura Support⁠)

For someone trying to conceive, that information may make cycle patterns easier to understand. But fertility decisions should not automatically be based on a consumer wearable alone.

Can a Smart Ring Tell You When Your Period Is Coming?

Potentially—with more information than a calendar alone.

Many conventional apps predict the next period by calculating forward from previous dates. That works reasonably well when cycles are highly regular, but becomes less reliable when cycle length changes.

Smart rings can combine menstrual history with physiological measurements.

For example, Oura’s current system uses temperature trends alongside signals including HRV to produce period predictions. Predictions continue to adjust as more individual data becomes available. (Oura Support⁠)

The key advantage is personalisation.

A wearable is not asking only, “What usually happens to women on cycle day 26?”

It can increasingly ask, “What is happening in this person’s physiology compared with her previous cycles?”

That is where wearables become genuinely interesting for women’s health.

Tracking a changing cycle or reproductive-health symptom? Create your free Sistapedia® profile to access trusted information and discover verified reproductive-health professionals.

What About Irregular Cycles?

This is also where limitations become clearer.

Irregular menstruation may occur for many reasons, including:

• adolescence;
• perimenopause;
• polycystic ovary syndrome (PCOS);
• thyroid disorders;
• pregnancy;
• breastfeeding;
• substantial changes in weight or energy availability;
• intense exercise;
• illness or stress;
• some medications;
• hormonal contraception.

A wearable may show that your pattern has changed. It generally cannot tell you why.

For example, repeated cycles without a clear post-ovulatory temperature shift could be consistent with anovulation—cycles in which ovulation does not occur—but that is not sufficient to establish a diagnosis or identify its cause.

This distinction matters.

The technology may be good at recognising an unusual signal while remaining poor at determining the clinical explanation behind it.

Can Wearables Identify Menstrual-Cycle Phases?

Evidence is developing rapidly.

A 2025 study published in npj Women’s Health examined machine-learning identification of menstrual phases using physiological data from a wrist-worn device, including skin temperature, heart rate, electrodermal activity and interbeat intervals. The research illustrates a broader shift away from calendar-only tracking towards multi-signal physiological modelling. (Nature⁠)

This does not mean every wearable algorithm performs equally well.

Algorithms differ. Sensors differ. Validation populations differ. Women with irregular cycles may also be underrepresented in datasets used to train or test some systems.

A device’s ability to recognise cycle phases therefore needs to be evaluated separately from the general concept of wearable cycle tracking.

Can a Smart Ring Detect Pregnancy?

Not reliably enough to replace a pregnancy test.

Early pregnancy causes physiological changes that a wearable may notice. Temperature can remain elevated, resting heart rate may change, sleep may shift and other signals may move away from an individual’s baseline.

But these changes are not specific to pregnancy.

Illness, stress, travel, alcohol, sleep disruption and other factors can affect some of the same measurements.

A wearable pattern might prompt someone to take a pregnancy test, but pregnancy should be confirmed using validated testing rather than interpreted from ring data.

Once pregnancy is known, some devices now provide dedicated pregnancy tracking. Oura, for example, offers Pregnancy Insights and adjusts its cycle features during and after pregnancy. (Oura Support⁠)

That is very different from diagnosing pregnancy.

What Can Smart Rings Tell Women About Perimenopause?

Perimenopause presents a particularly interesting challenge for wearable technology because the transition can involve changing cycles, sleep disruption, vasomotor symptoms such as hot flashes and shifts in temperature regulation.

A wearable may help someone document changes occurring over months or years.

It may reveal that:

• sleep has become more fragmented;
• night-time temperature patterns have changed;
• resting heart rate or HRV differs from previous baselines;
• cycle lengths are becoming more variable.

Some wearable platforms are now explicitly developing features around perimenopause. Oura’s current women’s-health suite, for example, includes a perimenopause feature alongside cycle and pregnancy tools. (Oura Support⁠)

But perimenopause remains a clinical life-stage assessment, not something a ring should independently diagnose.

This is particularly important because symptoms associated with perimenopause can overlap with thyroid disease, anaemia, sleep disorders, mood disorders and other health conditions.

Can a Smart Ring Detect PCOS or Endometriosis?

Not currently as a standalone diagnostic tool.

This is an area where consumers need to be particularly cautious about the difference between data collection and diagnosis.

PCOS is diagnosed using clinical criteria that may involve menstrual and ovulatory history, signs or biochemical evidence of androgen excess and ovarian findings, while excluding other possible causes.

Endometriosis likewise cannot be established simply because a wearable records poor sleep, elevated resting heart rate, pain-related physiological stress or cycle changes.

Wearables could nevertheless become valuable research tools.

Long-term datasets may reveal physiological patterns associated with symptoms, flare-ups or different stages of disease. Machine learning may eventually identify signals that improve screening or clinical decision-making.

That remains different from a consumer device telling someone: “You have endometriosis.”

Why Your Baseline Matters More Than Someone Else’s Number

Perhaps the most useful principle in wearable health is also the least dramatic.

Your trend is often more meaningful than another person’s number.

Skin-temperature deviations, resting heart rate and HRV can vary considerably between people. A smart ring’s strength comes from repeated measurement under relatively consistent conditions.

Over weeks and months, the device establishes a personal baseline.

A persistent deviation from that baseline may therefore be more informative than comparing your measurement with a generic population average.

This is why wearables may eventually become particularly useful in women’s health: reproductive physiology changes across puberty, menstrual cycles, pregnancy, postpartum recovery, perimenopause and menopause.

A static “normal” value cannot capture that complexity particularly well.

Longitudinal data can.

Smart Rings Are Not Medical Oracles

The risk comes when detailed data creates an illusion of certainty.

More measurements do not automatically equal more knowledge.

A ring might detect an elevated temperature without knowing whether the cause is progesterone, infection, disrupted sleep or environmental conditions.

It may identify an unusual cycle without identifying PCOS.

It may observe cardiovascular changes without diagnosing pregnancy.

It may document worsening sleep during perimenopause without determining whether sleep apnoea is also present.

Wearable data should therefore be considered another piece of health information—not a replacement for history-taking, examination, laboratory testing, imaging or clinical judgement.

Regulatory status matters too.

A consumer wellness feature and a regulated medical device are not equivalent. Oura explicitly states that its own Fertile Window feature is intended for cycle tracking and trying-to-conceive visibility rather than birth control, while its integration with Natural Cycles connects users to a separate FDA-cleared Class II medical device. (Oura Support⁠)

That distinction should always be clear before relying on wearable information for a medical or contraceptive decision.

When to Seek Professional Medical Assessment

Wearable data becomes most useful when it adds context to a conversation rather than replacing one.

Consider discussing your cycle with a healthcare professional if you notice persistent changes such as substantially altered cycle length, very heavy bleeding, prolonged absence of menstruation when pregnancy is not the explanation, persistent pelvic pain or repeated evidence that ovulation may not be occurring.

Seek medical assessment based on your symptoms even when the wearable says everything appears normal. Algorithms can miss clinically important problems.

Likewise, an unusual wearable reading without symptoms does not necessarily mean something is wrong.

If possible, bring several months of cycle dates, symptoms and relevant wearable trends to an appointment. Pattern information can be more useful than one isolated reading.

The Future Is Not the Ring—It Is the Data

The real significance of smart rings may eventually extend well beyond today’s period predictions.

Wearable devices can generate continuous longitudinal health datasets that historically did not exist outside research environments.

That creates opportunities for researchers to study how menstrual cycles interact with sleep, cardiovascular physiology, fertility, pregnancy, menopause and chronic reproductive-health conditions at scale.

It also creates substantial questions about algorithm quality, clinical validation and reproductive-data privacy.

The strongest future technology will not simply collect more information.

It will need to demonstrate that the information it produces is accurate, clinically meaningful and useful for the woman making a health decision.

For now, smart rings are best understood as sophisticated pattern-recognition tools.

They can show women signals that were once difficult to observe.

They cannot yet explain every signal they find.

FAQs

Can a smart ring accurately tell when I ovulate?

Some validated wearable algorithms can estimate ovulation more accurately than calendar prediction alone by analysing temperature and other physiological signals. Accuracy varies by device and individual, and wearable estimates should not automatically replace clinical fertility assessment or validated contraception methods.

Can an Oura Ring tell if I am pregnant?

Physiological patterns recorded by a ring may change during early pregnancy, but they are not specific enough to confirm pregnancy. Use an appropriate pregnancy test and seek clinical assessment where required.

Can a smart ring detect PCOS?

A smart ring cannot independently diagnose PCOS. It may identify irregular cycles, temperature patterns or possible changes in ovulation that could provide useful information to discuss with a healthcare professional.

Are smart rings reliable for birth control?

Do not assume that a general cycle-tracking feature is approved for contraception. Regulatory status varies by product and feature. Some wearables integrate with regulated contraceptive technologies, but these should be distinguished from general wellness or fertile-window tracking features.

Are smart rings useful during perimenopause?

They may be useful for documenting longitudinal changes in sleep, temperature, cardiovascular measurements and menstrual-cycle variability. These patterns can provide useful personal information, but they do not independently diagnose perimenopause or exclude other medical causes of symptoms.

Continue on Sistapedia®

For Sistas: Create your free Sistapedia® profile and continue exploring trusted reproductive-health information and verified professionals.

Share your experience: Your experience with cycle tracking or wearable health technology could help another woman understand her own. Share your story on Sistapedia® and apply for your free Pink Tick verification.

For healthcare professionals and experts: Establish your verified professional presence, publish educational content and strengthen discovery across the Sistapedia® ecosystem. Apply for Crown Verification through the Verification tab in your Sistapedia® profile.